Alveron Pharma

About Alveron Pharma

Alveron Pharma is focused on developing breakthrough therapies for haemorrhagic stroke, addressing a severe unmet medical need. Their mission is to improve outcomes for patients suffering from intracranial haemorrhage (ICH) by providing rapid, effective treatments.

Products & Services

OKL-1111:A potential breakthrough drug for the treatment of haemorrhagic stroke. It is a rapid, first-line therapy with a universal mode of action, not requiring anticoagulant identification. It is developed as a ready-to-use injection to eliminate time-consuming preparation, with pre-clinical data indicating a low risk of thrombotic overshoot.

Specialties

Haemorrhagic Stroke Treatment Intracranial Haemorrhage Therapy Rapid First-Line Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series Seed extension T: - FT: Series Seed extension	A: 5280000 MR: - FA: €5.0 million FAN: 5280000	D: 2024-12-06 FD: 2024-12-06	5 investors

Series Seed extension Latest

2024-12-06

$5.3M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Ben Nichols

Chief Executive Officer

S

Stephan Peters

Chief Scientific Officer

H

Hash Patel

Chief Operating Officer

A

Alex Zwiers

Chief Development Officer

E

Edwin Spaans

Clinical Director

M

Maxime Schreurs

Senior Program Manager

View 14 more team members with Pro

Unlock Full Team Directory

Recent News

Alveron Pharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised